Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4.
Considerable morbidity and mortality result from schistosomiasis, an affliction affecting an estimated 200 million people. Although schistosomicidal drugs and other control measures (including public hygiene and snail control) exist, the advent of an efficacious vaccine remains the most potentially powerful means for controlling this disease. We have targeted a vaccine candidate (large subunit of calpain, Sm-p80) because of its consistent immunogenicity, protective potential, and integral role in surface membrane biogenesis of schistosomes. Since surface membrane renewal appears to be one of the major phenomena employed by schistosomes to evade the host's immune system; an immune response directed against Sm-p80 should render the parasite susceptible to immune clearance from the host by both providing a focus of attack and by potentially impairing the membrane repair process. In the present study, we have employed DNA immunization protocols using Sm-p80 with plasmids encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). Sm-p80 by itself provided 39% protection (P = < or =0.0001) against challenge infection in C57BL/6 mice. This protection was increased to 44% (P = < or =0.0001) when the plasmid encoding GM-CSF was coadministered with Sm-p80 DNA. Coinjection of plasmid DNA encoding IL-4 with Sm-p80 DNA yielded a protection level of 42% (P = < or =0.0001). Statistically, the protection conferred by including GM-CSF, but not IL-4, was significantly greater than that when only Sm-p80 was used. Sm-p80 DNA by itself elicited strong responses that include IgG2A and IgG2B antibody isotypes. The introduction of GM-CSF DNA with Sm-p80 DNA led to distinct increases in total IgG and IgG1 titers, whereas the coadministration of IL-4 DNA with Sm-p80 DNA resulted in a slight elevation of IgG1 and IgG3 titers and in some reduction of IgG2A and IgG2B titers. Our data again indicate that Sm-p80 can be an excellent candidate for a schistosomiasis vaccine.
Siddiqui
Afzal A
AA
Department of Internal Medicine, Texas Tech University Health Sciences Center and Veterans Affairs Health Care System, Amarillo, Texas 79106, USA. siddiqui@ama.ttuhsc.edu
Phillips
Troy
T
Charest
Hugues
H
Podesta
Ron B
RB
Quinlin
Martha L
ML
Pinkston
Justin R
JR
Lloyd
Jenny D
JD
Paz
Michelle
M
Villalovos
Rachael M
RM
Pompa
Janet
J
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood; D016466:CHO Cells; D002154:Calpain / Q000502:physiology*; D006224:Cricetinae; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification; D015847:Interleukin-4 / Q000494:pharmacology*; D051379:Mice; D021122:Protein Subunits; D012550:Schistosoma mansoni / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000909:Antibodies, Helminth; D007074:Immunoglobulin G; D021122:Protein Subunits; D019444:Vaccines, DNA; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D002154:Calpain